1

Maestrini et al . S

Table e-1. Results of the logistic regression analyses with symptomatic intracerebral hemorrhage, excellent outcome (modified Rankin Scale [mRS] 0 or 1 or equal to pre-stroke mRS), good outcome (mRS 0 to 2 or equal to pre-stroke mRS), or death as dependent variables. Model 1: with neutrophils count. Model 2: with leukocytes count. Model 3: with neutrophil to lymphocyte ratio. See text for definitions. sICH = symptomatic intracerebral hemorrhage; NIHSS = National Institute Health Stroke Scale; CI = confidence interval; OTT = Onset-to-treatment; CRP = C-reactive protein; BP = blood pressure; MI = myocardial infarction; NLR = neutrophil to lymphocyte ratio; AF = atrial fibrillation.

Dependent variables / Logistic regression / Independent
variables / adjOR (95%CI) / P value / Variables entered into the model but not selected
Model 1 (with neutrophils)
sICH / Overall p value <0.001
R2 = 0.16
Well classified = 93.7 / Neutrophil count
Baseline NIHSS
Age
Sex
Platelets value / 1.21 (1.11-1.32)
1.06 (1.01-1.11)
1.04 (1.02-1.07)
2.24 (1.18-4.25)
0.99 (0.99-1.00) / <0.001
0.019
0.002
0.014
0.020 / OTT, Helsinki center, Antiplatelet therapy, Glycemia, CRP
Excellent outcome / Overall p value <0.001
R2 = 0.23
Well classified =69.4% / Neutrophils count
Baseline NIHSS
Age / 0.87 (0.82-0.93)
0.89 (0.87-0.92)
0.98 (0.97-0.99) / <0.001
<0.001
<0.001 / OTT, Sex, AF, Bridging therapy, Glycemia, CRP, Hematocrit
Good outcome / Overall p value <0.001
R2 = 0.32Well classified =72.3% / Neutrophils count
Baseline NIHSS
Age
Helsinki center / 0.86 (0.80-0.91)
0.87 (0.85-0.90)
0.95 (0.94-0.97)
0.72 (0.51-1.00) / <0.001
<0.001
<0.001
0.047 / OTT, Sex, Diabetes mellitus, AF, Antiplatelet therapy, Bridging therapy, Glycemia, CRP, Hematocrit
Death / Overall p value <0.001
R2 = 0.29
Well classified =88.9% / Neutrophil count
Baseline NIHSS
Age
Previous MI / 1.16 (1.08-1.24)
1.11 (1.07-1.15)
1.08 (1.05-1.10)
2.07 (1.10-3.90) / <0.001
<0.001
<0.001
0.024 / OTT, Helsinki center, Sex, AF, Antiplatelet therapy, Systolic BP, Glycemia, CRP, Hematocrit
Model 2 (with leukocytes)
sICH / Overall p value <0.001
R2 = 0.10
Well classified =93.6% / Baseline NIHSS
Age
Sex / 1.08 (1.04-1.13)
1.05 (1.02-1.08)
2.67 (1.43-4.97) / <0.001
<0.001
0.002 / Leukocyte count (p = 0.803), OTT, Helsinki center, Antiplatelet therapy, Glycemia, CRP, Platelets
Excellent outcome / Overall p value <0.001
R2 = 0.20
Well classified =68.8% / Baseline NIHSS
Age / 0.88 (0.86-0.91)
0.98 (0.96-0.99) / <0.001
<0.001 / Leukocyte count (p= 0.271), OTT, Sex, AF, Bridging therapy, Glycemia, CRP, Hematocrit
Good outcome / Overall p value <0.001
R2 = 0.29
Well classified =70.1% / Baseline NIHSS
Age / 0.87 (0.85-0.89)
0.96 (0.95-0.97) / <0.001
<0.001 / Leukocyte count (p= 0.160), OTT, Helsinki centre, Sex, Diabetes mellitus, AF, Antiplatelet therapy, Bridging therapy, Glycemia, CRP, Hematocrit
Death / Overall p value <0.001
R2 = 0.27
Well classified =89.1% / Baseline NIHSS
Age
Previous MI
CRP / 1.13 (1.09-1.17)
1.08 (1.05-1.10)
2.10 (1.12-3.92)
1.01 (1.00-1.02) / <0.001
<0.001
0.020
0.038 / Leukocyte count (p= 0.270), OTT, Helsinki center, Sex, AF, Antiplatelet therapy, Systolic BP, Glycemia, Hematocrit
Model 3 (with neutrophil to lymphocyte ratio)
sICH / Overall p value <0.001
R2 = 0.18
Well classified =93.8% / NLR
Baseline NIHSS
Age
Sex
Platelets / 1.11 (1.06-1.17)
1.05 (1.01-1.11)
1.04 (1.01-1.07)
2.23 (1.14-4.34)
1.00 (0.99-1.00) / <0.001
0.032
0.004
0.019
0.039 / OTT, Helsinki center, Antiplatelet therapy, Glycemia, CRP
Excellent outcome / Overall p value <0.001
R2= 0.25
Well classified =71.4% / NLR
Baseline NIHSS
Age
CRP / 0.85 (0.81-0.90)
0.90 (0.87-0.92)
0.98 (0.97-0.99)
1.01 (1.00-1.02) / <0.001
<0.001
<0.001
0.036 / OTT, Sex, AF, Bridging therapy, Glycemia, Hematocrit
Good outcome / Overall p value <0.001
R2= 0.33
Well classified =72.1% / NLR
Baseline NIHSS
Age
Antiplatelet therapy / 0.91 (0.86-0.95)
0.88 (0.85-0.90)
0.95 (0.94-0.96)
1.45 (1.02-2.06) / <0.001
<0.001
<0.001
0.038 / OTT, Helsinki center, Sex, Diabetes mellitus, AF, Bridging therapy, Glycemia, CRP, Hematocrit
Death / Overall p value <0.001
R2= 0.30
Well classified =89.4% / NLR
Baseline NIHSS
Age
Previous MI / 1.08 (1.03-1.13)
1.12 (1.07-1.16)
1.08 (1.06-1.11)
2.26 (1.19-4.29) / 0.001
<0.001
<0.001
0.013 / OTT, Helsinki center, Sex, AF, Antiplatelet therapy, Systolic BP, Glycemia, CRP, Hematocrit

e-References

e1. IST-3 collaborative group, Sandercock P, Wardlaw JM, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012; 379:2352-2363.

e2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587.

e3. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359:1317-1329.

e4. Hacke W, Donnan G, Fieschi C, et al.Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363:768-774.

e5. Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012; 379:2364-2372.

e6. Jauch EC, Saver JL, Adams HP, Jr., et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44:870-947.

e7. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19:604-607.

e8. Lyden P, Brott T, Tilley B, et al. Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke 1994; 25:2220-2226.